연구성과로 돌아가기

2024 연구자 정보 (685 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lim, Jong-Won
(Lim, JW) ⓘ 		Elect & Telecommun Res Inst, RF Power Components Res Sect, Daejeon 34129, South Korea
Elect & Telecommun Res Inst, Terr & Nonterr Integrated Telecommun Res Lab, Daejeon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.8] Improved frequency performance in AlGaN/GaN HEMTs on Si using hydrogen silsesquioxane-assisted gate
[JCR상위 70.4] Effects of parasitic gate capacitance and gate resistance on radiofrequency performance in LG=0.15 μm GaN high-electron-mobility transistors for X-band applications ⓘ 		SCIE ⓘ 25.8 ENGINEERING, ELECTRICAL & ELECTRONIC;MATERIALS SCIENCE, MULTIDISCIPLINARY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER
ENGINEERING, ELECTRICAL & ELECTRONIC;TELECOMMUNICATIONS ⓘ 		sangminwon@skku.edu;
sjchang@etri.re.kr; ⓘ
Won, Sang Min
(Won, SM) ⓘ 		교신저자 Sungkyunkwan Univ, Dept Elect & Comp Engn, Suwon 16419, South Korea ⓘ IXN-0563-2023
WON, SANG ⓘ 		0000-0002-5750-8628
WON, SANG ⓘ 		[JCR상위 25.8] Improved frequency performance in AlGaN/GaN HEMTs on Si using hydrogen silsesquioxane-assisted gate ⓘ SCIE ⓘ 25.8 ENGINEERING, ELECTRICAL & ELECTRONIC;MATERIALS SCIENCE, MULTIDISCIPLINARY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER ⓘ sangminwon@skku.edu; ⓘ
Ahn, Sang Hoon
(Ahn, SH) ⓘ 		Yonsei Univ, Severance Hosp, Coll Med, Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
Yonsei Univ, Coll Med, Seoul, South Korea
Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea ⓘ 		AAV-2600-2020
AFM-2603-2022
SANG-HOON, AHN
Ahn, Sang Hoon ⓘ 		0000-0002-3629-4624
Ahn, Sang Hoon ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
[JCR상위 3.2] Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study ⓘ 		SCIE ⓘ 3.2 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr;
drwon1@snu.ac.kr;hanseungbong@gmail.com;ksukorea@yuhs.ac; ⓘ
Byun, Hyeji
(Byun, H) ⓘ 		Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Vessel Organ Interact Res Ctr, Daegu 41566, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Dihydrotestosterone Enhances MICA-Mediated Immune Responses to Epstein-Barr Virus-Associated Gastric Carcinoma ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ puppu04050@naver.com;qkek0810@naver.com;cmy1004g@knu.ac.kr;ihappy278@knu.ac.kr;yshggid@gmail.com;2009045032@knu.ac.kr;inukjung@knu.ac.kr;hyosun1102@duksung.ac.kr;hkang72@knu.ac.kr; ⓘ
Cho, Yong Kyun
(Cho, YK) ⓘ 		Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med, 29 Saemunan Ro, Seoul 03181, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr; ⓘ
Choi, Chang-min
(Choi, CM) ⓘ 		교신저자 Univ Ulsan, Asan Med Ctr, Coll Med, Div Pulmonol & Crit Care Med,Dept Internal Med, 88 Olymp ro 43-gil, Seoul 05505, South Korea
Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oncol, Seoul 05505, South Korea
Univ Ulsan, Asan Med Ctr, Coll Med, Dept Pulm & Crit Care Med, Seoul, South Korea
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea ⓘ
ⓘ 		0000-0002-2881-4669
Choi, Chang-Min ⓘ 		[JCR상위 25.9] Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer
[JCR상위 46.8] Real-world outcome of crizotinib for anaplastic lymphoma kinase-positive lung cancer: Multicenter retrospective analysis in South Korea ⓘ 		SCIE ⓘ 25.9 ONCOLOGY
ONCOLOGY;RESPIRATORY SYSTEM ⓘ 		hyeonhwa1@gmail.com;jclee@amc.seoul.kr;droij@chonnam.ac.kr;dognose79@naver.com;leemk@pusan.ac.kr;ckpaul@catholic.ac.kr;kyleemd@kuh.ac.kr;cmcksj@catholic.ac.kr;ccm@amc.seoul.kr;
drhrkim10@gmail.com;simi20083132@gmail.com; ⓘ
Chung, Woo Jin
(Chung, WJ) ⓘ 		Keimyung Univ, Dept Internal Med, Sch Med, Daegu 42601, South Korea
Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea
Keimyung Univ, Sch Med, Daegu, South Korea
Keimyung Univ, Keimyung Univ Dongsan Hosp, Sch Med, Dept Internal Med, Daegu 42601, South Korea
Keimyung Univ, Dongsan Med Ctr, Dept Internal Med, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
[JCR상위 1.7] Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
[JCR상위 4.4] BENEFICIAL EFFECT OF COMBINED RADIATION THERAPY IN ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT OF HEPATOCELLULAR CARCINOMA PATIENTS WITH MAIN PORTAL VEIN TUMOR THROMBOSIS OR BILE DUCT INVASION
[JCR상위 25.9] The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib
[JCR상위 43.9] Diagnostic performance of procalcitonin for bacterial infection in severe alcoholic hepatitis compared with C-reactive protein ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY ⓘ 		mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr;
jheo@pusan.ac.kr;
kmggood111@naver.com;ssong3004@naver.com;magnolia1103@naver.com;kbs9225@cu.ac.kr;chung50@dsmc.or.kr;chlee1@cu.ac.kr;psyoung0419@gmail.com;eworldcup@gmail.com;yokweon@knu.ac.kr;gastro@dsmc.or.kr;jangha106@dsmc.or.kr;deblue00@naver.com;gsnrs@naver.com;
p100100@dau.ac.kr;H00175@paik.ac.kr; ⓘ
de Carvalho, Lucas Mezione
(de Carvalho, LM) ⓘ 		제1저자 Kyungpook Natl Univ, Coll Agr & Life Sci, Dept Appl Biol, Daegu, South Korea ⓘ
ⓘ 		0000-0002-5457-0629
Mezione de Carvalho, Lucas ⓘ 		[JCR상위 25.9] Effect of fluorescent brighteners on the insecticidal activity of Bacillus thuringiensis var. kurstaki and LdMNPV on Lymantria dispar asiatica in Korea ⓘ SCIE ⓘ 25.9 BIOCHEMISTRY & MOLECULAR BIOLOGY;ENTOMOLOGY;PHYSIOLOGY ⓘ leeky@knu.ac.kr; ⓘ
Heo, Jeong
(Heo, J) ⓘ 		교신저자 Pusan Natl Univ, Pusan Natl Univ Hosp, Biomed Res Inst, Coll Med, Busan 49241, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea
Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
Pusan Natl Univ, Pusan Natl Univ Hosp, Coll Med, Pusan, South Korea
Pusan Natl Univ, Pusan, South Korea
Pusan Natl Univ Hosp, Med Res Inst, Pusan, South Korea
Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea
Pusan Natl Univ, Coll Med, Dept Internal Med, Pusan, South Korea
Pusan Natl Univ Hosp, Biomed Res Inst, Pusan, South Korea
Pusan Natl Univ, Dept Internal Med, Coll Med, Pusan, South Korea ⓘ 		MHQ-1390-2025
Q-1055-2018
Heo, Jeong
Lee, Jeong-Hoon ⓘ 		0000-0003-0961-7851
Heo, Jeong ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
[JCR상위 1.7] Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
[JCR상위 4.4] BENEFICIAL EFFECT OF COMBINED RADIATION THERAPY IN ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT OF HEPATOCELLULAR CARCINOMA PATIENTS WITH MAIN PORTAL VEIN TUMOR THROMBOSIS OR BILE DUCT INVASION
[JCR상위 4.4] VALIDATION OF AN ARTIFICIAL INTELLIGENCE MODEL FOR PREDICTION OF HEPATOCELLULAR CARCINOMA RISK AFTER ORAL ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C
[JCR상위 1.0] VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
[JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma ⓘ 		SCIE ⓘ 1.0 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY ⓘ 		mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr;
jheo@pusan.ac.kr;
mfyuen@hkucc.hku.hk;
tom.evans@barinthusbio.com;
bsangro@unav.es; ⓘ
Hong, Gun Young
(Hong, GY) ⓘ 		Kwangju Christian Hosp, Dept Internal Med, 37 Yangnim Ro, Gwangju 503715, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr; ⓘ
Hwang, Hwal-Su
(Hwang, HS) ⓘ 		Kyungpook Natl Univ, Coll Agr & Life Sci, Dept Appl Biol, Daegu, South Korea
Kyungpook Natl Univ, Sustainable Agr Res Ctr, Gunwi, South Korea
Kyungpook Natl Univ, Coll Agr & Life Sci, Dept Plant Med, Daegu 41566, South Korea
Kyungpook Natl Univ, Inst Plant Med, Daegu 41566, South Korea
Gyeongsang Natl Univ, Dept Plant Med, Daegu 52828, South Korea
Kyungpook Natl Univ, Dept Appl Biol, Daegu, South Korea ⓘ
ⓘ 		0000-0002-6000-4893
Hwang, Hwal-Su ⓘ 		[JCR상위 25.9] Effect of fluorescent brighteners on the insecticidal activity of Bacillus thuringiensis var. kurstaki and LdMNPV on Lymantria dispar asiatica in Korea
[JCR상위 13.2] The Fumigation Toxicity of Three Benzoate Compounds against Phosphine-Susceptible and Phosphine-Resistant Strains of Rhyzopertha dominica and Sitophilus oryzae
[JCR상위 13.2] Genetic Diversity and DNA Barcoding of Thrips in Bangladesh
[JCR상위 39.5] A new species of Braunsia (Hymenoptera, Braconidae, Agathidinae), a natural enemy of Cydalima perspectalis (Lepidoptera, Crambidae) from South Korea: species description and notes on its biology ⓘ 		SCIE ⓘ 13.2 BIOCHEMISTRY & MOLECULAR BIOLOGY;ENTOMOLOGY;PHYSIOLOGY
ENTOMOLOGY ⓘ 		leeky@knu.ac.kr;
munir93@knu.ac.kr;bgtwo2@knu.ac.kr;junrankim@korea.kr;bskim79@korea.kr;leeky@knu.ac.kr;
k.fatemabsmrau@gmail.com;bgtwo2@naver.com;wjdgns3771@naver.com;leeky@knu.ac.kr;viruskil@anu.ac.kr;
ikang@knu.ac.kr; ⓘ
Hwang, Jae Seok
(Hwang, JS) ⓘ 		Keimyung Univ, Keimyung Univ Dongsan Hosp, Sch Med, Dept Internal Med, Daegu 42601, South Korea
Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Internal Med, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib
[JCR상위 55.4] Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study ⓘ 		SCIE ⓘ 25.9 ONCOLOGY ⓘ kmggood111@naver.com;ssong3004@naver.com;magnolia1103@naver.com;kbs9225@cu.ac.kr;chung50@dsmc.or.kr;chlee1@cu.ac.kr;psyoung0419@gmail.com;eworldcup@gmail.com;yokweon@knu.ac.kr;gastro@dsmc.or.kr;jangha106@dsmc.or.kr;deblue00@naver.com;gsnrs@naver.com;
dyk1025@yuhs.ac; ⓘ
Hwang, Sang Youn
(Hwang, SY) ⓘ 		제1저자 Dongnam Inst Radiol & Med Sci, Dept Internal Med, Busan 46033, South Korea ⓘ
ⓘ 		0000-0003-2750-9379
HWANG, SANGYOUN ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma ⓘ SCIE ⓘ 25.9 ONCOLOGY ⓘ mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr; ⓘ
Jang, Byoung Kuk
(Jang, BK) ⓘ 		Keimyung Univ, Dept Internal Med, Sch Med, Daegu 42601, South Korea
Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea
Keimyung Univ, Sch Med, Daegu, South Korea
Keimyung Univ, Keimyung Univ Dongsan Hosp, Sch Med, Dept Internal Med, Daegu 42601, South Korea ⓘ
ⓘ 		0000-0002-8950-0866
Jang, Byoung Kuk ⓘ 		[JCR상위 25.9] Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
[JCR상위 1.7] Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis
[JCR상위 4.4] BENEFICIAL EFFECT OF COMBINED RADIATION THERAPY IN ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT OF HEPATOCELLULAR CARCINOMA PATIENTS WITH MAIN PORTAL VEIN TUMOR THROMBOSIS OR BILE DUCT INVASION
[JCR상위 25.9] The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib
[JCR상위 3.2] Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
GASTROENTEROLOGY & HEPATOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		mongmani@daum.net;who54@hanmail.net;jheo@pusan.ac.kr;phorni@naver.com;juya0630@naver.com;yikiyoun@hanmail.net;deblue00@naver.com;psyoung0419@gmail.com;chung50@dsmc.or.kr;jangha106@dsmc.or.kr;wytak@knu.ac.kr;
jheo@pusan.ac.kr;
kmggood111@naver.com;ssong3004@naver.com;magnolia1103@naver.com;kbs9225@cu.ac.kr;chung50@dsmc.or.kr;chlee1@cu.ac.kr;psyoung0419@gmail.com;eworldcup@gmail.com;yokweon@knu.ac.kr;gastro@dsmc.or.kr;jangha106@dsmc.or.kr;deblue00@naver.com;gsnrs@naver.com;
drwon1@snu.ac.kr;hanseungbong@gmail.com;ksukorea@yuhs.ac; ⓘ
Jang, Jae Young
(Jang, JY) ⓘ 		Soonchunhyang Univ, Seoul Hosp, Dept Internal Med, 59 Daesagwan Ro, Seoul 04401, South Korea
Soonchunhyang Univ, Inst Digest Res, Coll Med, Digest Dis Ctr, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 25.9] Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
[JCR상위 3.2] Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021: a nationwide, multicentre, retrospective cohort study ⓘ 		SCIE ⓘ 3.2 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		gudwns21@korea.ac.kr;dumbo83@korea.ac.kr;2002021168@korea.ac.kr;ahnsh@yuhs.ac;drwon1@snu.ac.kr;jmyangdr@catholic.ac.kr;jyjang@schmc.ac.kr;yokweon@knu.ac.kr;choyk2004.cho@samsung.com;yoonjun@snu.ac.kr;gyh228803@gmail.com;djkim@hallym.ac.kr;sonjh@hanyang.ac.kr;jin@inha.ac.kr;yaheaven@inje.ac.kr;eug203@korea.ac.kr;jkpark@ildong.com;umsh@korea.ac.kr;
drwon1@snu.ac.kr;hanseungbong@gmail.com;ksukorea@yuhs.ac; ⓘ
페이지 이동: